|
WO2021036793A1
|
|
Pyroptosis-induced immunotherapy
|
|
WO2021031893A1
|
|
Prostatitis treatment
|
|
WO2020063999A1
|
|
Mono halogen or methyl-substituted 5-ht2b antagonists with increased activity
|
|
CN110747514A
|
|
High-throughput single-cell small RNA library construction method
|
|
US2019381052A1
|
|
MLKL Inhibitors
|
|
WO2020001392A1
|
|
Cathepsin c inhibitors
|
|
WO2019242576A1
|
|
Treating demyelinating disease
|
|
KR20210020104A
|
|
Promotes immune response
|
|
WO2020237586A1
|
|
Prosthesis for the lung and the use thereof
|
|
WO2020237588A1
|
|
Drug target of idiopathic pulmonary fibrosis
|
|
WO2020237587A1
|
|
Animal model of idiopathic pulmonary fibrosis, its construction method and use
|
|
CN112007038A
|
|
Heme oxygenase-1 inducer and application thereof
|
|
WO2020215267A1
|
|
Use of ntcp inhibitors in preventing and treating hepatocarcinogenesis
|
|
CN112218878A
|
|
NTCP inhibitors
|
|
WO2019024707A1
|
|
Synthesizing metal nanoparticles on individual thiol-rich tags as single-molecule probes
|
|
EP3612223A1
|
|
Treating Male Senescence
|
|
CN110573509A
|
|
MLKL inhibitors
|
|
WO2019144390A1
|
|
Multiplexed immunosignal amplification using hybridization chain reaction-based method
|
|
WO2019144391A1
|
|
Use of ishcr for exm and solvent-based tissue clearing
|
|
WO2018133835A1
|
|
Nucleoside analogue regulating mammalian circadian rhythm
|
